9th Circ. Rejects Rehearing On Norvir Antitrust Deal
By Christopher Norton ( August 21, 2009, 4:29 PM EDT) -- A federal appeals court has rejected a bid for an en banc rehearing of its decision to limit a settlement to $10 million in a class action alleging that Abbott Laboratories illegally jacked up the prices of its market-dominating HIV drug Norvir, sticking to its finding that the plaintiffs failed to state a claim in light of recent case law....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.